Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.
<b/> Identifying molecular and cellular features associated with resistance to targeted BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches. Integrated, comparative analysis of genomic and functional data in sensitive and resistant cell lines unveils novel targetable regulators of resistance to MAPK pathway inhibition in melanoma. Cancer Discov; 7(8); 799-801. ©2017 AACR.See related article by Eskiocak et al., p. 832.